You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Biogen drug shows signs of promise

NEW YORK — Biogen Idec Inc. said Thursday its longer-lasting injectable multiple sclerosis drug, peginterferon beta-1a, helped reduce patients’ risk of relapse by 36 percent when given every two weeks, meeting the goals of a late-stage study.

The medicine reduced patients’ risk of flare-ups by 28 percent when dosed every four weeks compared with placebo, the Weston, Mass., firm said in a statement. Based on the results, Biogen said it plans to apply this year for regulatory approval in Europe and the United States.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week